


CLAIMS

What is Claimed is:

1. A compound of formula:



or a pharmaceutically acceptable salt thereof, wherein

R¹ is selected from the group

H,

C₁₋₁₀ alkyl,

C₁₋₁₀ alkyl substituted by up to three groups selected from aryl, cycloalkyl, heteroaryl, heterocycle, NR¹⁰R¹¹, OR¹², SR¹², halogen, COR¹³, CO₂R¹³, CONR¹³R¹⁴, SO₂NR¹³R¹⁴, SOR¹³, SO₂R¹³, CN and NO₂, wherein the aryl, cycloalkyl, heteroaryl, and heterocycle groups may each independently be substituted by up to three groups selected from NR¹⁰R¹¹, OR¹², SR¹², , halogen, COR¹³, CO₂R¹³, CONR¹³R¹⁴, SO₂NR¹³R¹⁴, SOR¹³, SO₂R¹³, CN and NO₂,

aryl,

aryl substituted by up to three groups selected from lower alkyl, NR¹⁰R¹¹, OR¹², SR¹², , halogen, COR¹³, CO₂R¹³, CONR¹³R¹⁴, SO₂NR¹³R¹⁴, SOR¹³, SO₂R¹³, CN and NO₂,

heteroaryl,
heteroaryl substituted by up to three groups selected from lower alkyl,
 $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
 SOR^{13} , SO_2R^{13} , CN and NO_2 ,
heterocycle,
heterocycle substituted by up to three groups selected from lower alkyl,
 $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
 SOR^{13} , SO_2R^{13} , CN and NO_2 ,
 C_{3-10} cycloalkyl,
 C_{3-10} cycloalkyl substituted by up to three groups selected from lower alkyl
 $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
 SOR^{13} , SO_2R^{13} , CN and NO_2 ,
 C_{2-10} alkenyl,
 C_{2-10} alkenyl substituted by up to three groups selected from $\text{NR}^{10}\text{R}^{11}$,
 OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} ,
CN and NO_2 , and
 C_{2-10} alkynyl, substituted by up to three groups selected from $\text{NR}^{10}\text{R}^{11}$,
 OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} ,
CN and NO_2 ;

R^2 , R^3 and R^4 are independently selected from the group consisting of

H,
 $\text{NR}^{10}\text{R}^{11}$,
 OR^{12} ,
 SR^{12} ,
 C_{1-10} alkyl,
 C_{1-10} alkyl substituted by up to three groups selected from cycloalkyl,
heteroaryl, heterocycle, $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} ,
 $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ; and wherein the
cycloalkyl, heteroaryl, and heterocycle groups may each independently be
substituted by up to three groups selected from lower alkyl, $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} ,

halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

heteroaryl, heteroaryl substituted by up to three groups selected from lower alkyl, $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

heterocycle, substituted by up to three groups selected from lower alkyl, $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

C_{3-10} cycloalkyl,

C_{3-10} cycloalkyl substituted by up to three groups selected from lower alkyl, $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

C_{2-10} alkenyl,

C_{2-10} alkenyl substituted by up to three groups selected from $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

C_{2-10} alkynyl, and

C_{2-10} alkynyl substituted by up to three groups selected from $\text{NR}^{10}\text{R}^{11}$, OR^{12} , SR^{12} , halogen, COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, $\text{SO}_2\text{NR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , CN and NO_2 ,

Provided that at least one of R^2 , R^3 or R^4 is not H.

R^5 , R^6 , R^7 and R^8 are independently selected from the group

H,

lower alkyl,

lower alkyl substituted by hydroxy or alkoxy,

$\text{NR}^{15}\text{R}^{16}$,

OH,

OR^{17} ,


SR^{17} ,

halogen,

COR^{17} ,
 CO_2R^{17} ,
 $\text{CONR}^{17}\text{R}^{18}$,
 $\text{SO}_2\text{NR}^{17}\text{R}^{18}$,
 SOR^{17} ,
 SO_2R^{17} , and
 CN ;

R^9 is selected from the group

H,



COR^{17} ;

R^{10} and R^{11} are independently selected from the group

H,

COR^{13} ,

CO_2R^{13} ,

$\text{CONR}^{13}\text{R}^{14}$,

SO_2R^{13} ,

$\text{SO}_2\text{NR}^{13}\text{R}^{14}$,

lower alkyl,

lower alkyl substituted by hydroxy, alkoxy or $\text{NR}^{15}\text{R}^{16}$,

cycloalkyl,

cycloalkyl substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$,

heterocycle, and

heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$,

or, alternatively, $\text{NR}^{10}\text{R}^{11}$ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more lower alkyl, OR^{12} , COR^{13} , CO_2R^{13} , $\text{CONR}^{13}\text{R}^{14}$, SOR^{13} , SO_2R^{13} , and $\text{SO}_2\text{NR}^{13}\text{R}^{14}$;

R^{12} is selected from the group

H,
lower alkyl,
 COR^{13} ,
 $\text{CONR}^{13}\text{R}^{14}$,
 C_{2-6} alkyl substituted by hydroxy, alkoxy, or $\text{NR}^{15}\text{R}^{16}$, cycloalkyl,
cycloalkyl substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$,
heterocycle, and
heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$;

R^{13} and R^{14} are independently selected from the group

H,
lower alkyl,
 C_{2-6} alkyl substituted by hydroxy, alkoxy, or $\text{NR}^{15}\text{R}^{16}$,
cycloalkyl,
cycloalkyl substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$,
heterocycle, and
heterocycle substituted by hydroxy, alkoxy, lower alkyl, or $\text{NR}^{15}\text{R}^{16}$,

or, alternatively, $\text{NR}^{13}\text{R}^{14}$ can form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more lower alkyl, OR^{17} , COR^{17} , CO_2R^{17} , $\text{CONR}^{17}\text{R}^{18}$, SO_2R^{17} , and $\text{SO}_2\text{NR}^{17}\text{R}^{18}$;

R^{15} is selected from the group

H,

lower alkyl,
COR¹⁷, and
CO₂R¹⁷; and

R¹⁶, R¹⁷ and R¹⁸ are independently selected from the group

H, and
lower alkyl,

or, alternatively, NR¹⁵R¹⁶ and NR¹⁷R¹⁸ can each independently form a ring having 3 to 7 atoms, said ring optionally including one or more additional hetero atoms;

R¹⁹ and R²⁰ are independently selected from the group

H, and
lower alkyl; and

R²¹ is selected from
lower alkyl, and

C₂₋₆ alkyl substituted by hydroxy, alkoxy or NR¹⁵R¹⁶,


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein R¹ is selected from aryl and aryl substituted by CN and CONR¹³R¹⁴.

3. The compound of claim 1 wherein R¹ is selected from lower alkyl.

4. The compound of claim 2 wherein R² is C₁₋₁₀ alkyl substituted by OR¹² or NR¹⁰R¹¹.

5. The compound of claim 3 wherein R^2 is OR^{12} .
6. The compound of claim 1 wherein R^3 is H.
7. The compound of claim 1 wherein R^3 and R^4 are H.
8. The compound of claim 1 wherein R^4 is C_{1-10} alkyl substituted by $NR^{10}R^{11}$.
9. The compound of claim 1 wherein R^5 is halogen.
10. The compound of claim 1 having the formula



1a.

11. A compound selected from the group:
 (±)-3-[7-[3-(2-Hydroxy-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile ;
 (±)-3-[7-[3-(2-Diethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile ; and
 (±)-3-[7-[3-(2-Dimethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzonitrile .
12. A compound selected from the group:

(±)-3-(3-(4-Methoxy-phenyl)-4-methyl-7-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl)-benzonitrile ;

(±)-3-[7-[3-(2-Diethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzamide ;

(±)-3-[7-[3-(2-Dimethylamino-ethyl)-phenylamino]-3-(4-methoxy-phenyl)-4-methyl-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl]-benzamide ; and

(±)-3-(3-(4-Methoxy-phenyl)-4-methyl-7-{3-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-2-oxo-3,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-1-yl)-benzamide .

13. The compound

(+)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

14. The compound

(-)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

15. The compound

(±)-3-(2-Bromo-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1,4-dimethyl-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and pharmaceutically acceptable carrier or excipient.

17. A method for treating cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.

18. A method of controlling cancer comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of claim 1.

19. The method of claim 17 wherein the cancer is breast, colon or hepatic cancer.

20. The method of claim 18 wherein the cancer is breast or colon cancer.

21. A compound selected from the group:

(±)-Acetic acid 2-{3-[8-(3-cyano-phenyl)-6-(4-methoxy-phenyl)-5-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-phenyl}-ethyl ester and

(±)-Methanesulfonic acid (2-{3-[8-(3-cyano-phenyl)-6-(4-methoxy-phenyl)-5-methyl-7-oxo-5,6,7,8-tetrahydro-pyrimido[4,5-d]pyrimidin-2-ylamino]-phenyl}-ethyl)-ester,